GTU Stock Overview
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Oncternal Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.32 |
| 52 Week High | US$11.80 |
| 52 Week Low | US$4.04 |
| Beta | 1.37 |
| 1 Month Change | 0% |
| 3 Month Change | -38.71% |
| 1 Year Change | 17.70% |
| 3 Year Change | -96.95% |
| 5 Year Change | n/a |
| Change since IPO | -94.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| GTU | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.3% | -2.5% |
| 1Y | 17.7% | -19.4% | -0.4% |
Return vs Industry: GTU underperformed the German Biotechs industry which returned 35.8% over the past year.
Return vs Market: GTU exceeded the German Market which returned 4.1% over the past year.
Price Volatility
| GTU volatility | |
|---|---|
| GTU Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GTU's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine GTU's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 29 | Jim Breitmeyer | www.oncternal.com |
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company’s clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
Oncternal Therapeutics, Inc. Fundamentals Summary
| GTU fundamental statistics | |
|---|---|
| Market cap | €23.13m |
| Earnings (TTM) | -€36.63m |
| Revenue (TTM) | €728.40k |
31.8x
P/S Ratio-0.6x
P/E RatioIs GTU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GTU income statement (TTM) | |
|---|---|
| Revenue | US$785.00k |
| Cost of Revenue | US$29.75m |
| Gross Profit | -US$28.97m |
| Other Expenses | US$10.51m |
| Earnings | -US$39.48m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.68 |
| Gross Margin | -3,690.19% |
| Net Profit Margin | -5,029.17% |
| Debt/Equity Ratio | 0% |
How did GTU perform over the long term?
See historical performance and comparison